Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Revenue (2021 - 2025)

Historic Revenue for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $51.3 million.

  • Rhythm Pharmaceuticals' Revenue rose 5427.51% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.3 million, marking a year-over-year increase of 5492.22%. This contributed to the annual value of $130.1 million for FY2024, which is 6806.06% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Revenue stood at $51.3 million, which was up 5427.51% from $48.5 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Revenue peaked at $51.3 million during Q3 2025, and registered a low of $35000.0 during Q1 2021.
  • Moreover, its 5-year median value for Revenue was $19.2 million (2023), whereas its average is $19.3 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Revenue surged by 418000.0% in 2022, and later skyrocketed by 2594.45% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Revenue (Quarter) stood at $1.8 million in 2021, then surged by 383.76% to $8.8 million in 2022, then surged by 175.7% to $24.2 million in 2023, then surged by 72.61% to $41.8 million in 2024, then rose by 22.63% to $51.3 million in 2025.
  • Its Revenue was $51.3 million in Q3 2025, compared to $48.5 million in Q2 2025 and $32.7 million in Q1 2025.